Amedeo Smart

Free Medical Literature Service



Colorectal Neoplasms

  Free Subscription


1 Adv Exp Med Biol
1 BMC Cancer
4 Br J Cancer
1 Int J Cancer
1 J Clin Oncol

    Adv Exp Med Biol

  1. GENDRON FP, Placet M, Arguin G
    P2Y2 Receptor Functions in Cancer: A Perspective in the Context of Colorectal Cancer.
    Adv Exp Med Biol. 2017 Aug 17. doi: 10.1007/5584_2017.
    >> Share

    BMC Cancer

  2. WINTHER SB, Osterlund P, Berglund A, Glimelius B, et al
    Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9.
    BMC Cancer. 2017;17:548.
    >> Share

    Br J Cancer

  3. LEVI F, Karaboue A, Saffroy R, Desterke C, et al
    Pharmacogenetic determinants of outcomes on triplet hepatic artery infusion and intravenous cetuximab for liver metastases from colorectal cancer (European trial OPTILIV, NCT00852228).
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    >> Share

  4. YUAN C, Bao Y, Sato K, Nimptsch K, et al
    Influence of dietary insulin scores on survival in colorectal cancer patients.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    >> Share

  5. YANG SS, Li XM, Yang M, Ren XL, et al
    FMNL2 destabilises COMMD10 to activate NF-kappaB pathway in invasion and metastasis of colorectal cancer.
    Br J Cancer. 2017 Aug 17. doi: 10.1038/bjc.2017.
    >> Share

  6. YUAN Z, Baker K, Redman MW, Wang L, et al
    Dynamic plasma microRNAs are biomarkers for prognosis and early detection of recurrence in colorectal cancer.
    Br J Cancer. 2017 Aug 15. doi: 10.1038/bjc.2017.
    >> Share

    Int J Cancer

  7. MEESTER RGS, Doubeni CA, Zauber AG, van Ballegooijen M, et al
    Impact of Adenoma Detection on the Benefit of Faecal Testing versus Colonoscopy for Colorectal Cancer.
    Int J Cancer. 2017 Aug 17. doi: 10.1002/ijc.30933.
    >> Share

    J Clin Oncol

  8. DOTAN E, Cohen SJ, Starodub AN, Lieu CH, et al
    Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer.
    J Clin Oncol. 2017 Aug 17:JCO2017739011. doi: 10.1200/JCO.2017.73.9011.
    >> Share

Free Medical Abstracts
Privacy Policy

© Amedeo 1997-2016